Products Tavaborole 5% Topical Solution
Tavaborole 5% Topical Solution Approved Completed ⚡ Active Interest: 43/100
Onychomycosis, Tinea Unguium
Oct 22, 2015 → Jul 27, 2017
About Tavaborole 5% Topical Solution Tavaborole 5% Topical Solution is a approved stage product being developed by Pfizer for Onychomycosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03405818. Target conditions include Onychomycosis, Tinea Unguium.
What happened to similar drugs? 1 of 9 similar drugs in Onychomycosis were approved
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT03405818 Approved Completed Oct 22, 2015 Jul 27, 2017 Onychomycosis
Product Company Stage Hype Score NVXT Solution + Vehicle of test product Sun Pharmaceutical Phase 2 NVXT topical + Placebo (Vehicle) Topical Sun Pharmaceutical Phase 2 SCH 56592 + SCH 56592 + SCH 56592 + SCH 56592 + Terbinafine + Placebo Merck Phase 2 terbinafine + Placebo + terbinafine + Placebo Novartis Phase 3 terbinafine hydrogen chloride + amorolfine nail lacquer Novartis Phase 3 terbinafine + Placebo + terbinafine + Placebo Novartis Phase 3 AN2690 Pfizer Phase 2 AN2690, 2.5% + AN2690, 5% + AN2690, 7.5% + Vehicle Pfizer Phase 2 AN2690 Solution, 5.0% + AN2690 Solution, 7.5% Pfizer Phase 2 AN2690 Topical Solution, 5% + Solution Vehicle Pfizer Phase 3 AN2690 + AN2690 Pfizer Phase 2 AN2690 Solution, 5.0% Pfizer Phase 2 AN2690, 2.5% + AN2690, 5% + AN2690, 7.5% + AN2690 Solution Vehicle Pfizer Phase 2 AN2690 Pfizer Phase 2 AN2690 Topical Solution, 5% + Solution Vehicle Pfizer Phase 3 AN2690 + AN2690 + AN2690 Pfizer Phase 1 Albaconozole + Placebo + Albaconozole + Placebo + Albaconozole + Placebo GSK plc Phase 1 Itraconazole 100mg capsules + Itraconazole 200mg tablets + Placebo tablets GSK plc Phase 3 Albaconazole tablet 400mg + Albaconazole 100mg capsules, then albaconazole 400mg tablet GSK plc Phase 1 Albaconazole 100mg + Albaconazole 200mg + Albaconazole 400mg + Albaconazole 400mg + Placebo 400 mg GSK plc Phase 2